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patients aged 65 years or older with DM (ICD-9-CM
code = 250.xx) were identiﬁed. The personal informa-
tion on socio-demographic characteristics, self-perceived
health status, co-existing medical conditions and other
measures were from the MCBS survey. The use of emer-
gency department (ED) was measured by number of ED
visits. A multivariate count regression model was used 
in the analysis. RESULTS: Of 1646 patients, 57% were
female; 81% were white; and 57% were current smokers.
The average number of ED visits was 74 per 100 patients
(SD = ±14.5). There were 35 percents of these patients
who had at least 1 emergency department visit. The
results from the multivariate regression model show that
predictors of ED visits were current smoker, poor in 
self-perceived health status, with 3 or more difﬁculties in
activity of daily living, having cardiovascular diseases.
Gender, race, education, living arrangement, Medicaid
insurance status, and residence were not signiﬁcant
factors to predict ED visits while controlling other
factors. CONCLUSIONS: This study shows that smoking
cessation and improving management in co-exsiting car-
diovascular diseases in older patients with diabetes may
reduce preventable ED visits.
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OBJECTIVES: To obtain the incremental cost for avoid-
ing a transition from a diagnosed IGT to diabetes through
a treatment based in the use of the Acarbose drug com-
pared to the normal practice. METHODS: Modelisation
of the health and economic consequences (direct costs for
the health system), in a period of 40 months, of imple-
menting Acarbose or a non-drug treatment to a popula-
tion of 1000 subjects diagnosed of IGT. The efﬁcacy,
adverse events, and the follow up of the pharmacological
treatment data were obtained from a controlled clinical
trial: STOP-NIDDM. The resources’ cost data were
obtained from published studies focused on the Spanish
Health System. The differential resources’ use of both
treatments (visits, tests, etc.) was actually discussed with
an expert in diabetes. RESULTS: The incremental cost of
avoiding the transition to type 2 DM from a IGT state
with the pharmacological treatment based on the use of
Acarbose is about €3386, and the incremental cost per
year of diabetes avoided is about €1736. Additionally the
evaluated treatment has signiﬁcant results reducing car-
diovascular events. CONCLUSION: In order to evaluate
all the positive effects of the treatment, a longer-term cost-
beneﬁt analysis and a comparison of the pharmacologi-
cal treatment of Acarbose with other 2 DM prevention
alternatives (basically the ones related to the life style)
would be needed.
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OBJECTIVE: To compare the association of congestive
heart failure (CHF) risk between pioglitazone use and
insulin use in type 2 diabetes patients. METHODS:
Adults with type 2 diabetes who initiated pioglitazone 
or insulin (INS) treatment between January 1999 and
December 2001 were identiﬁed and an “index date”
assigned based on the ﬁrst antidiabetic drug prescription.
The sample was restricted to those continuously en-
rolled at least 12 months before and at least 3 months
after therapy initiation. Patients with CHF diagnosis 
or digoxin use in the preindex period, troglitazone use
during preindex or follow up, or any oral antidiabetic use
other than metformin or a sulfonylurea (ﬁnal 6 months
of preindex only) was excluded. INS patients were
matched (1 :1) to pioglitazone patients based on a differ-
ence of no more than ±0.01 in the estimated propensity
score for pioglitazone therapy; propensity was modeled
using logistic regression; controlling for demographics,
comorbidities, preindex utilization costs; and postindex
treatment duration. CHF risk (based on ≥1 diagnoses
during follow up) was examined using Cox proportional
hazards models. Further, risk of inpatient hospitalization
for CHF also was explored. RESULTS: A total of 1668
matched pairs were identiﬁed for pioglitazone vs. insulin
comparison. Mean patient age was 51 years; 51% were
male. Crude CHF incidence was higher in the INS group
(4.0% vs. 2.0% for INS group at 2 years, p = 0.001). In
Cox proportional hazards models controlling for age 
and preindex total Health care costs, 2-year CHF risk was
signiﬁcantly lower for the pioglitazone group (HR =
0.501, 95% CI = 0.331, 0.758; p = 0.001) than for 
the INS group; ﬁndings were similar for inpatient 
hospitalization for CHF (HR = 0.263, 95% CI = 0.135,
0.511; p = 0.0001). Differences were similar when 
pioglitazone monotherapy was compared with insulin.
CONCLUSION: Pioglitazone use appears to be associ-
ated with lower CHF risk versus INS use in type 2 
diabetes patients.
